Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-NME1 Antibody (1U277) is a Mouse antibody targeting NME1. Anti-NME1 Antibody (1U277) can be used in FCM,ICC/IF.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 μL | $199 | 7-10 days |
Description | Anti-NME1 Antibody (1U277) is a Mouse antibody targeting NME1. Anti-NME1 Antibody (1U277) can be used in FCM,ICC/IF. |
Alias | NME/NM23 nucleoside diphosphate kinase 1, NM23-H1, NM23, NDPK-A, NDPKA, NDKA, NBS, NB, GAAD, AWD |
Ig Type | Monoclonal Mouse IgG1 |
Clone | 1U277 |
Reactivity | Human |
Verified Activity | 1. Immunofluorescence staining of Human NME1 in Hela cells. Cells were fixed with 4% PFA, permeabilzed with 0.3% Triton X-100 in PBS, blocked with 10% serum, and incubated with Mouse anti-Human NME1 monoclonal antibody (1:60) at 37°C 1 hour. Then cells were stained with the Alexa Fluor® 594-conjugated Goat Anti-mouse IgG secondary antibody (red) and counterstained with DAPI (blue). Positive staining was localized to cytoplasm. 2. Flow cytometric analysis of Human NME1 expression on HeLa cells. The cells were treated according to manufacturer’s manual (BD Pharmingen™ Cat. No. 554714), stained with purified anti-Human NME1, then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells. |
Application | FCM,ICC/IF |
Recommended Dose | ICC-IF: 1:20-1:100; FCM: 1:25-1:100 |
Antibody Type | Monoclonal |
Host Species | Mouse |
Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human NME1 / NDKA (rh NME1 / NDKA; TMPY-04467; NP_000260.1; Ala2-Glu152). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. |
Purification | Protein A |
Appearance | Liquid |
Formulation | 0.2 μm filtered solution in 20 mM MES, 100 mM NaCl, 10% Trehalose, 0.02% Tween 80, pH 6.0 |
Research Background | NME1, also known as Nucleoside Diphosphate Kinase A (NDK-A), or NM23-H1, belongs to the NDK family. NM23-H1 is known to have a metastasis suppressive activity in many tumor cells. Recent studies have shown that the interacting proteins with NM23-H1 which mediate cell proliferation, may act as modulators of the metastasis suppressor activity. The interacting proteins with NM23-H1 can be classified into 3 groups. The first group of proteins can be classified as upstream kinases of NM23-H1 such as CKI and Aurora-A/STK15. The second group of proteins acts as downstream effectors for the regulation of specific gene transcriptions, GTP-binding protein functions, and signal transduction in the Erk signal cascade. The third group of proteins can be classified as bi-directionally influencing binding partners of NM23-H1. As a result, the interactions with NM23-H1 and binding partners have implications in the biochemical characterization involved in metastasis and tumorigenesis. NDKA is increased in human postmortem cerebrospinal fluid (CSF), a model of global brain insult, suggesting that measurement in CSF and, more importantly, in plasma may be useful as a biomarker of stroke. Additionally, NM23-H1 significantly reduces metastasis without effects on primary tumor size and was the first discovered metastasis suppressor gene. |
Conjucates | Unconjugated |
Others Formats | FITC/PE |
Antibody Types Available | 3 |
Immunogen | Recombinant Human NME1 / NDKA protein (TMPY-04467) |
Antigen Species | Human |
Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.